HealthcareServices

Global Next Generation Cancer Diagnostics Industry Trends and Market Forecast 2026–2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the next generation cancer diagnostics market from 2026–2035 with trusted insights from The Business Research Company

How is the Next Generation Cancer Diagnostics Market size predicted to change over the forecast window of 2026–2035?_x000D_

The next generation cancer diagnostics market size has seen rapid expansion in recent years. It is forecast to grow from $14.4 billion in 2025 to $16.29 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.2%. The historical increase can be attributed to several factors including rising cancer incidence rates, advancements in genomic sequencing technologies, increasing clinical adoption of biomarker-based diagnostics, expanded funding for oncology research, and a growing demand for precision diagnostics._x000D_

_x000D_

The next generation cancer diagnostics market size is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $26.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.9%. This expansion during the forecast period is driven by increasing adoption of personalized medicine approaches, rising investments in advanced cancer screening programs, growing use of minimally invasive diagnostic methods, expansion of companion diagnostics development, and increasing integration of AI-driven clinical decision support. Prominent trends for the forecast period encompass increasing adoption of liquid biopsy technologies, rising use of multi-omics diagnostic platforms, growing integration of AI-based cancer analytics, expansion of personalized oncology diagnostics, and an enhanced focus on early-stage cancer detection._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp_x000D_

_x000D_

Which Drivers Are Contributing To The Expansion Of The Next Generation Cancer Diagnostics Market?_x000D_

The expanding requirement for personalized medicines is projected to propel the growth of the next generation cancer diagnostics market going forward. Personalized medicines refer to medical treatments specifically designed for an individual’s genetic makeup, lifestyle, and environment to ensure the most effective therapy for that particular patient. This heightened demand stems from the increasing occurrence of chronic and rare diseases, which necessitate focused, patient-specific therapies for more effective treatment outcomes. Next generation cancer diagnostics facilitate personalized medicine by providing accurate molecular insights that guide customized treatment strategies based on an individual patient’s unique genetic and tumor profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, marking a notable increase from the six approvals recorded in 2022. Therefore, the rising demand for personalized medicines is a key factor driving the growth of the next generation cancer diagnostics market._x000D_

_x000D_

What Segment Classifications Make Up The Next Generation Cancer Diagnostics Market?_x000D_

The next generation cancer diagnostics market covered in this report is segmented –_x000D_

_x000D_

1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms_x000D_

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer_x000D_

3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis_x000D_

4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis_x000D_

5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings_x000D_

_x000D_

Subsegments:_x000D_

1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing_x000D_

2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems_x000D_

3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays_x000D_

4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays_x000D_

5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays_x000D_

6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems_x000D_

_x000D_

Which Market Trends Are Opening Growth Opportunities In The Next Generation Cancer Diagnostics Market?_x000D_

Leading companies in the next generation cancer diagnostics market are concentrating on developing innovative solutions, such as artificial intelligence-driven multi-modal diagnostic platforms, to improve early detection, personalized treatment, and clinical decision-making. These artificial intelligence-driven multi-modal diagnostic platforms are advanced systems that utilize artificial intelligence to integrate and analyze various types of biological data, including genomic, proteomic, imaging, and clinical information, to deliver more accurate and personalized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, unveiled OncoIncytes, a multi-modal cancer diagnostic platform tailored for precision oncology. This platform integrates diverse data types, such as circulating tumor DNA, single-cell circulating tumor cells, RNA information, and detailed protein profiles of 150 proteins at the single-cell level. Leveraging a 1080-gene panel powered by AI and machine learning, OncoIncytes provides highly sensitive and specific insights to enhance clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform allows for personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell’s proprietary iDiscover application from a CLIA-certified laboratory._x000D_

_x000D_

Which Key Market Players Are Investing In Expansion And Innovation Within The Next Generation Cancer Diagnostics Market?_x000D_

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd._x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report_x000D_

_x000D_

Which Regions Are Projected To Dominate The Next Generation Cancer Diagnostics Market In The Coming Years?_x000D_

North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Next Generation Cancer Diagnostics Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=30336&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Next Generation Cancer Diagnostics Market 2026, By The Business Research Company#_x000D_

_x000D_

Oncology Companion Diagnostics Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report_x000D_

_x000D_

Next Generation Gynecological Cancer Diagnostics Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report_x000D_

_x000D_